Lehman meeting was printed in brokerage
Rumor emenated from traders talking to each
Technicaly , vrtx has been in a downtrend since 2/2/98 at
This means that if you bought vrtx at anytime since
and did not sell it when it lifted, you
would have had a loss.
vrtx does appear to have
bottomed for the present..
(abacavir), a nucleoside analog reverse
transcriptase inhibitor which appears "to have greater
antiviral activity than other drugs in this class". (see
Glaxo W's PR today 10:46 EST)
Looks like Glaxo
W. is working to market the whole cocktail with all
of the X resistance, etc, sequences studied in Ph
III, plus offer more effective analogs. Any clinicians
out there who would have something to say about using
the Glaxo suite of anti retrovirals since adverse
event profiles, resistance, peds dosing, etc. etc.
combo concerns being studied in PH III when
co-developed by one comapny? (Amprenavir is VRTX +_Glaxo W)
hi and thanks for your response.
still - i
would like to know if you will tell me -
you know about the lehman meeting?
where did you
hear the rumor?
what is the "downtrend"
Yeah, VX-710 could also be big-I agree that this
will be the difference for the company if there is a
quick follow-on. The hep c stuff is exciting buy years
away. Potential blockbuster stuff but lots of
competition. Again, I do think the distinction between the
company and the stock is important to keep in mind both
for the investor and management in these biotechs. It
can be painful at times-that's why I believe they
should a) be traded short-term or b) locked away for 10
years and ignored.Best of luck in your investing.
after the highly likely (IMO) Amprenavir
approval. So next up... the Incel research (VX-710) the
mutidrug resistance inhibitor which is in numerous
different CA trials, or maybe the Hepatitic C work with
is key. I have seen the odd thing of stocks pulling
back after approval (sell on the news) but perhaps
that is with more gap in pipeline than the situation
suggests. It is an interesting thing though so I will try
to gather a list of examples that might elucidate.
I think VRTX has an awareness of this. While the
science vs. the stock/and other R&D financing concerns
make an uneasy set of priorities, one is need of the
other, though I hope that a certain critical mass is
reached where the stock will follow on up with scientific
and drug development achievement. The late-stage
biotech dream. Idealistic perhaps, but then the odds of
making it this far and surviving as a company are